Biotech Values

[randychub]

NSCLC - Squal - Some other trials. I do not consider erbitux competition for squal. I will say that I believe erbitux will eventually be frontline in NSCLC.

I would guess that if we lower the chemo doseage and keep survival rates in line with these survival rates that someone will have an interest in taking this on to additional trials.


From ASCO 2002 ------Trial to determine survival of Patients of Advanced (stage IIIB or IV) NSCLC.(John Hainsworth m.d.). this 330 patient trial tried to determine the overall survival of people taking chemo consisting of Carboplatin and Paclitaxel compared to the older Cisplatin based regimes. In a nutshell it’s results were as follows----One year survival- 40%, Two year survival- 19%, Three year survival- 7% and four year survival -<4%.


1000 patient trial which in essence reported that Iressa did not help first line NSCLC. Intact 2 was a Carb/Pac chemo trial like the report above with the inclusion of two different doses of Iressa added. In these types of trials they basically use a “mean” number for survival so you have to do some rough estimating. The mean survival of patients taking chemo alone was 9.9 months, patients taking chemo and lo-dose of Iressa was 9.8 months and patients taking chemo and hi-dose Iressa was 8.7 months. These results are what forced Astra to go for and get a mono rating Iressa.

From BMY/Imclone ASCO 2003- Abstract 2592---This was a small 31 patient (all stage IV) Phase I/II trial using the exact chemo’s as above trying to look for dosing and primary results. Well the main output of this study was that it accomplished a PR in 9 (29%) patients and SD in 11 (35.5%) patients for a total disease control of 64.5%. The median overall survival is 472 DAYS or 15.73 months.

This is from an old IMCL post. I looked into this data and could not find any completed trials with better data.

Randy